Lung, Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Volunteers
Health Professionals
What is the purpose of this trial?
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alison Johnson
- Andrea Brennan
- Beverly Drucker, MD, PhD
- Clarice Grens
- D. Barry Boyd, MD, MS
- Emily Collier, MD
- Emily Duffield, APRN
- Emily Kopas, APRN, OCN
- Frederick Wilson, MD, PhD
- Harold Tara Jr, MD
- James Vredenburgh, MD
- John Glendening
- Jose Morales-Marin
- Karishma Mehra, MBBS
- Kayla Martello
- Larisa Fleysher
- Laura Sabourin
- M. Sung Lee, MD
- Madeline Santiago
- Marianne Davies, NP, DNP, MSN, BSN
- Michael Cohenuram, MD
- Osarugue Otasowie
- Pawan Karanam, MD
- Renee Moye
- Roy S. Herbst, MD, PhD
- Sarah Goldberg, MD, MPH
- Scott Gettinger, MD
- So Yeon Kim, MD
- Vanna Dest
- Vidya Kesavan
- Zia Rahman, MD
- Last Updated11/14/2024
- Study HIC#2000037003